Roche Ticlid
Executive Summary
The company says it has no agreement with Torpharm or any other company regarding the marketing of a generic ticlopidine. Roche has not sued any paragraph IV ANDA holders and supported Apotex/Torpharm's claim to 180-day exclusivity as the first to file an ANDA for ticlopidine. FDA agreed, blocking Purepac, the only company with a tentative approval for the product, from marketing its ticlopidine ANDA ("The Pink Sheet" Aug. 17, p. 24)